BioCryst Pharmaceuticals, Inc.  

(Public, NASDAQ:BCRX)   Watch this stock  
Find more results for BCRX
15.34
+0.08 (0.52%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.87 - 15.57
52 week 7.85 - 16.83
Open 15.15
Vol / Avg. 542,815.00/1.10M
Mkt cap 1.11B
P/E     -
Div/yield     -
EPS -0.72
Shares 72.47M
Beta 2.43
Inst. own 91%
Aug 7, 2015
Q2 2015 BioCryst Pharmaceuticals Inc Earnings Call - 11:00AM EDT - Add to calendar
Aug 7, 2015
Q2 2015 BioCryst Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Jun 23, 2015
BioCryst Pharmaceuticals Inc at JMP Securities Life Sciences Conference
Jun 2, 2015
BioCryst Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 20, 2015
BioCryst Pharmaceuticals Inc Annual Shareholders Meeting
May 12, 2015
BioCryst Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 8, 2015
Q1 2015 BioCryst Pharmaceuticals Inc Earnings Call - Webcast
May 8, 2015
Q1 2015 BioCryst Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -222.15% -332.08%
Operating margin -211.40% -336.35%
EBITD margin - -335.05%
Return on average assets -45.60% -48.66%
Return on average equity -86.89% -121.30%
Employees 50 -
CDP Score - -

Address

4505 Emperor Blvd Ste 200
DURHAM, NC 27703-8457
United States - Map
+1-919-8591302 (Phone)
+1-919-8591314 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Company’s Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.

Officers and directors

Jon P. Stonehouse President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Thomas R. Staab II Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
Age: 50
Bio & Compensation  - Reuters
Yarlagadda S. Babu Ph.D. Senior Vice President - Drug Discovery
Age: 62
Bio & Compensation  - Reuters
Lynne Powell Senior Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
William P. Sheridan Senior Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Alane P. Barnes Vice President, General Counsel, and Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
George B. Abercrombie Non-Executive Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Director
Age: 58
Bio & Compensation  - Reuters
Stanley C. Erck Independent Director
Age: 66
Bio & Compensation  - Reuters
Nancy J. Hutson Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters